Opinion|Videos|October 22, 2024
Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC
Author(s)Joshua K. Sabari, MD, Sandip Patel, MD
Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.
Advertisement
Episodes in this series
Advertisement
Related to this article
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Perioperative pembrolizumab plus neoadjuvant cisplatin and gemcitabine did not significantly improve EFS vs placebo in cisplatin-eligible MIBC in KEYNOTE-866.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.
Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.
Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.
The FDA based its approval of pembrolizumab on findings from the phase 2 KEYNOTE-158 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors
3
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
4
Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC
5